

**“Immunology and Innate Immunity are Keys to Cancer Treatment”
Conclusions of the Roundtable of internationally renowned speakers,
including winners of the 2011 Nobel Prize in Medicine**

*Immunotherapy and innate immunity targets are at the heart of the
search for long-term, high quality of life responses for patients*

Paris and Marseille, May 21, 2012: [Bristol-Myers Squibb France](#) and [Innate Pharma](#) are pleased to announce that the roundtable "**Innate immunity: from revolutionary discovery to revolution in therapy**", held on 15 May in Paris was a great success, with the participation of more than 150 international guests from across medical and scientific fields. The panel of internationally renowned speakers included special guests **Bruce Beutler** and **Jules Hoffman**, winners of the 2011 Nobel Prize in Medicine. The event highlighted the recent successes of immunotherapies and the significant therapeutic potential of targeting innate immunity.

Prof. Philippe Kourilsky, Chair of Immunology at the College de France, who chaired the event said: *“Immunology is now a major source of new anti-cancer products: after years of targeting the tumor itself with undeniable success, targeting the immune system could achieve high quality long term responses in cancer patients. Stratification is now one of the major challenges of immunotherapy: we have tools but we need usable immunological biomarkers to perform stratification of patients and tumors. Combinations with tumor-targeting therapies, as well as combinations of different immunotherapies will be also necessary. In this context, there is no doubt that innate immunity manipulation will permit the emergence of groundbreaking therapeutic strategies.”*

Mike Seeley, President of Bristol-Myers Squibb France, said: *“It is a very exciting time. As a number of speakers said today, in five to ten years, we will be looking at cancer in a completely different way. I am very proud that Innate Pharma and Bristol-Myers Squibb could be part of a breakthrough in the treatment of cancer, as controlling simultaneously checkpoints on innate and adaptive immunity could be keys to prevent immune escape.”*

Hervé Brailly, CEO of Innate Pharma, said: *“We thank the panelists for the excellent debate which reflected the importance of close collaboration between researchers, clinicians and industry which is at the heart of Innate Pharma’s business model. Clearly, we have reached an inflexion point: after 30 years of hope, we now see the major clinical benefits brought by immunotherapy and know how to address the numerous targets discovered by academic research with antibodies.”*

**Webcast, interviews, summary and more on
www.immunite-innee.com**

About the roundtable

The round table "**Innate immunity: from revolutionary discovery to revolution in therapy**", took place on 15 May in Paris, and included:

- **Two 2011 Nobel prize winners in Medicine, Dr. Jules Hoffmann** from the Institute of Molecular and Cellular Biology at the University of Strasbourg, and **Dr. Bruce Beutler** of the Center for the Genetics of Host Defense at the University of Texas, whose scientific discoveries have contributed to the elucidation of mechanisms of activation of the innate immune system;
- **Professor Jean-Yves Blay**, Professor of Medical Oncology, Centre Leon Berard in Lyon, chairing the European organization for the research of cancer treatments (EORTC), who has developed a wealth of experience in cancer immunotherapy;
- **Dr. Nils Lonberg**, Senior Vice President in charge of research and development of biological drugs, Bristol-Myers Squibb, who participated in the development of the first antibody modulator of T cells;
- **Professor Eric Vivier**, Director, Center for Immunology Marseille-Luminy, who is a co-founder of Innate Pharma and a specialist of Natural Killer cells.
- **Philippe Kourilsky**, Chair of Immunology at the College de France and former Director of the Pasteur Institute, moderated the discussion.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose goal is to discover, develop and deliver innovative drugs that help patients prevail over serious diseases. For more information, please visit www.bmsfrance.fr or follow us on Twitter at <http://twitter.com/#!/bmsnews>.

About Innate Pharma

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases. The Company specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. The mechanisms controlling these cells were described at the end of the 90s, notably by the teams of the scientists who founded Innate Pharma. This innovative approach has been validated by two major biopharmaceutical partners: Bristol-Myers Squibb in cancer and Novo Nordisk A/S in inflammation. Learn more about Innate Pharma at www.innate-pharma.com.

Bristol-Myers Squibb Forward-Looking Statements

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2010, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Innate Pharma Forward-Looking Statements

This press release contains certain forward-looking statements. Although Innate Pharma (the company) believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (<http://www.amf-france.org>) or on Innate Pharma’s website. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Contacts

ATCG Press

Marielle Bricman
Director

Mob.: +33 (0)6 26 94 18 53
mb@atcg-partners.com

Innate Pharma

Laure-Hélène Mercier
Director, Investor Relations

Phone: +33 (0)4 30 30 30 87
Laure-Helene.Mercier@innate-pharma.fr

Bristol-Myers Squibb France

Catherine Liabeuf
Associated Director Public Affairs

Phone: +33 (0)1 58 83 87 92
catherine.liabeuf@bms.com